Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor Scripts Rebounding, Pfizer Says; Cholesterol Category Still Has Life

Executive Summary

Pfizer sees signs of a rebound in Lipitor (atorvastatin) prescriptions over the past six weeks, U.S. Pharmaceuticals President Pat Kelly said during Pfizer's June 17 analysts meeting in New York
Advertisement

Related Content

Tough Sell? Pfizer CEO Outlines Lipitor Game Plan For Generic Zocor
Tough Sell? Pfizer CEO Outlines Lipitor Game Plan For Generic Zocor
Combo Rx Product Market Potential Is Enhanced By Single Copay – Analysts
Combo Rx Product Market Potential Is Enhanced By Single Copay – Analysts
Pfizer Launches Inspra; Will Help Company Reach $54 Bil. In 2004
Pfizer Stops Swinging For The Fences; Combo Products Are Big Opportunity
Zocor Rx Growth Picks Up In June; Merck Hopes Crestor Helps Revive Market
Pfizer Sizes Up Rx Industry; Will Wall Street See Bulk As Strategic Asset?
Lipitor Sales Slowdown Reflects Overall Rx Market Trend, Pfizer Says
Lipitor Sales Slowdown Reflects Overall Rx Market Trend, Pfizer Says
Advertisement
UsernamePublicRestriction

Register

PS042008

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel